Product
Nanoliposomal Irinotecan + Oxaliplatin + Capecitabine + Cadonilimab
1 clinical trial
8 indications
Indication
Nanoliposomal IrinotecanIndication
CadonilimabIndication
OxaliplatinIndication
CapecitabineIndication
First-LineIndication
Advanced CancerIndication
Pancreatic adenocarcinomaIndication
Substance Use DisorderClinical trial
Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II StudyStatus: Recruiting, Estimated PCD: 2026-08-30